RAPT Therapeutics Appoints Scott Braunstein to Board of Directors

RAPT Therapeutics has filed a Form 3 (Initial Statement of Beneficial Ownership) for newly appointed Director Scott Braunstein, effective June 21, 2025.

Accepted by SEC EDGAR 06/24/2025 - 04:23 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

RAPT Therapeutics has filed a Form 3 (Initial Statement of Beneficial Ownership) for newly appointed Director Scott Braunstein, effective June 21, 2025. The filing discloses that Mr. Braunstein currently holds no beneficial ownership of any securities in the company, either direct or indirect.

Key details from the filing:

• Position: Director (non-employee)
• Filing Status: Individual filing
• Business Address: 561 Eccles Avenue, South San Francisco, CA 94080
• No ownership of non-derivative securities reported
• No ownership of derivative securities (options, warrants, etc.) reported

The Form 3 was signed by Rodney Young as Attorney-in-Fact on June 24, 2025, fulfilling the SEC requirement for new insiders to report their initial securities ownership within 10 days of becoming an officer, director, or 10% owner.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new director appointed to RAPT Therapeutics (RAPT) board in June 2025?

Scott Braunstein was appointed as a Director of RAPT Therapeutics, Inc. The Form 3 filing dated June 28, 2025 indicates his initial statement of beneficial ownership following his appointment as director on June 21, 2025.

How many shares of RAPT Therapeutics does Scott Braunstein own upon appointment?

According to the Form 3 filing, Scott Braunstein owns no securities beneficially at the time of his appointment as director. The filing explicitly states 'No securities are beneficially owned' in the Explanation of Responses section.

Does Scott Braunstein hold any derivative securities in RAPT Therapeutics?

No, the Form 3 filing shows that Scott Braunstein does not hold any derivative securities (such as options, warrants, or convertible securities) in RAPT Therapeutics at the time of his appointment as director.

What positions does Scott Braunstein hold at RAPT Therapeutics as of June 2025?

According to the Form 3 filing, Scott Braunstein serves as a Director at RAPT Therapeutics. He is not listed as an officer or 10% owner, with only the 'Director' box checked in the relationship section of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Braunstein Scott

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/21/2025

3. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Rodney Young, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.